Current Cancer Reports
Current Cancer Reports (CCR) (eISSN: 2661-3166) is an open access, continuously published, international, refereed journal dedicated to publish articles covering all areas of carcinogenesis, prevention, diagnosis, treatment, drug development and related policy.
The journal aims at promoting research communications, and providing a platform for doctors, researchers, physicians, pharmacists and healthcare professionals to find the most recent advances in all areas of cancer-related fields. Current Cancer Reports accepts original research articles, reviews, minireviews, case reports, image data, novel hypothesis and rapid communication covering all respects of carcinogenesis and cancer therapy.
The columns of the journal include, but not limited to:
• Original articles and new techniques in cancer research and therapy
• Quick reports
• Case reports
• Clinicopathologic discussion
• Discussion of clinical case
• Expert views
• Exchange of experience
• Novel hypothesis
• Correspondence
• Publish the original incoming letter
• Academic contending/Debate
• etc.
2022-04-21
Current Cancer Reports is indexed in PubMed (NIH Funded Articles, NLM ID: 101757994), CAS, Scilit, BASE, J-Gate, EuroPub, Dimensions, Crossref, Google Scholar, Baidu Scholar, NLB of Singapore, etc., and being indexed in other authoritative academic databases is under application.
The mock Impact Factor of Current Cancer Reports is 1.20.
Vol 7 (2025)
Published: 2025-04-15
Page 254-268
Zhimin Lu, Sicong Xu, Guofeng Zhao, Ziyi Niu, Guoxin Hou
Background: Tumor cells are characterized by a higher production of ribosomes, which are necessary for maintaining enhanced cell growth and subsequent cell division.
Aim: The study aimed to develop a prognostic RPL score for hepatocellular carcinoma (HCC) and explore its association with immune evasion mechanisms mediated by tumor microenvironment alterations.
Methods: Using single-sample gene set enrichment analysis (ssGSEA), an RPLscore was constructed to estimate the dysregulation of ribosomal protein large (RPL) genes. The expression of RPL genes and their association with clinical outcomes and the tumor microenvironment (TME) were systematically investigated using bulk-seq and single-cell RNA-seq (scRNA-seq).
Results: High expression levels of RPL in HCC were associated with poorer overall survival (OS) (P < 0.001). The RPL score evaluated the RPL gene and verified its independent prognostic value for both OS and relapse-free survival (P = 0.0074 and P < 0.001, respectively). TME analysis indicated that RPL gene dysregulation was closely associated with T cell exhaustion, myeloid-derived suppressor cell (MDSC) infiltration, and vascular dysplasia may be promoted by arginine deficiency (P = 7.6 × 10-10). The scRNA-seq data suggested that the RPL score was positively and significantly associated with the tumor biodiversity score (ITH score).
Conclusion: The study highlights the prognostic value of the RPL score and its potential role in mediating immune evasion of HCC, which may provide an impetus for the development of new targets for the treatment of HCC.
| eISSN: 2661-3166 Abbreviation: Curr Cancer Rep Editor-in-Chief: Prof. Yingyu Cui Publishing Frequency: Continuous publication Article Processing Charges (APC): Click here for more details Publishing Model: Open Access |
ISSN 2661-3166
